International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers
Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Wom...
Saved in:
| Published in | International journal of cancer Vol. 122; no. 9; pp. 2017 - 2022 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.05.2008
Wiley-Liss |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0020-7136 1097-0215 1097-0215 |
| DOI | 10.1002/ijc.23340 |
Cover
| Abstract | Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy‐seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow‐up questionnaire was completed a mean of 3.9 years (range 1.5–10.3 years) after genetic testing. One thousand five hundred thirty‐one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one‐half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one‐half of women at risk for breast cancer rely on screening alone. © 2008 Wiley‐Liss, Inc. |
|---|---|
| AbstractList | Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy‐seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow‐up questionnaire was completed a mean of 3.9 years (range 1.5–10.3 years) after genetic testing. One thousand five hundred thirty‐one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one‐half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one‐half of women at risk for breast cancer rely on screening alone. © 2008 Wiley‐Liss, Inc. Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone. Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone.Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5-10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone. Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy-seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow-up questionnaire was completed a mean of 3.9 years (range 1.5–10.3 years) after genetic testing. One thousand five hundred thirty-one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one-half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one-half of women at risk for breast cancer rely on screening alone. Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening. The authors report on preventive practices in women with mutations from 9 countries and examine differences in uptake according to country. Women with a BRCA1 or BRCA2 mutation were contacted after receiving their genetic test result and were questioned regarding their preventive practices. Information was recorded on prophylactic mastectomy, prophylactic oophorectomy, use of tamoxifen and screening (MRI and mammography). Two thousand six hundred seventy‐seven women with a BRCA1 or BRCA2 mutation from 9 countries were included. The follow‐up questionnaire was completed a mean of 3.9 years (range 1.5–10.3 years) after genetic testing. One thousand five hundred thirty‐one women (57.2%) had a bilateral prophylactic oophorectomy. Of the 1,383 women without breast cancer, 248 (18.0%) had had a prophylactic bilateral mastectomy. Among those who did not have a prophylactic mastectomy, only 76 women (5.5%) took tamoxifen and 40 women (2.9%) took raloxifene for breast cancer prevention. Approximately one‐half of the women at risk for breast cancer had taken no preventive option, relying solely on screening. There were large differences in the uptake of the different preventive options by country of residence. Prophylactic oophorectomy is now generally accepted by women and their physicians as a cancer preventive measure. However, only the minority of women with a BRCA1 or BRCA2 mutation opt for prophylactic mastectomy or take tamoxifen for the prevention of hereditary breast cancer. Approximately one‐half of women at risk for breast cancer rely on screening alone. © 2008 Wiley‐Liss, Inc. |
| Author | Moller, Pal Lubinski, Jan Foulkes, William D. Friedman, Eitan Metcalfe, Kelly A. Wagner, Teresa Couch, Fergus Domchek, Susan Rosen, Barry Birenbaum‐Carmeli, Daphna Ghadirian, Parviz Kim‐Sing, Charmaine Klijn, Jan Ainsworth, Peter Lynch, Henry Sun, Ping Manoukian, Siranoush Gronwald, Jacek Tung, Nadine Narod, Steven A. |
| AuthorAffiliation | 13 The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel 9 Department of Human Genetics, McGill University, Montréal, QC, Canada 8 Department of Medicine, McGill University, Montréal, QC, Canada 20 Beth Israel Deaconess Medical Centre, Boston, MA 14 British Columbia Cancer Agency Vancouver, BC, Canada 2 Women’s College Research Institute, Women’s College Hospital, University of Toronto, ON, Canada 12 The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel 18 Department of Oncology, University of Pennsylvania, Philadelphia, PA 11 Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands 4 Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland 15 London Regional Program, London Health Sciences Centre, London, ON, Canada 19 Division of Senology, Department of Gynecology, Medical University of Vienna and Private Trust for Breast Health, Austria 10 Department of Oncology, McGill Univer |
| AuthorAffiliation_xml | – name: 18 Department of Oncology, University of Pennsylvania, Philadelphia, PA – name: 20 Beth Israel Deaconess Medical Centre, Boston, MA – name: 15 London Regional Program, London Health Sciences Centre, London, ON, Canada – name: 21 Medical Genetics Service, Department of Experimental Oncology and Laboratories, Istituto Nazionale Tumori, Milan, Italy – name: 11 Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands – name: 3 Department of Nursing, University of Haifa, Haifa, Israel – name: 16 Department of Gynecologic Oncology, Princess Margaret Hospital, Toronto, Canada – name: 17 Department of Hematology, University of Pennsylvania, Philadelphia, PA – name: 9 Department of Human Genetics, McGill University, Montréal, QC, Canada – name: 13 The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – name: 1 Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada – name: 14 British Columbia Cancer Agency Vancouver, BC, Canada – name: 4 Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland – name: 12 The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel – name: 2 Women’s College Research Institute, Women’s College Hospital, University of Toronto, ON, Canada – name: 6 Section for Inherited Cancer, Department of Medical Genetics, Rikshospitalet-Radiumhospitalet Medical Centre, Oslo, Norway – name: 5 Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE – name: 7 Epidemiology Research Unit, Research Centre, Centre Hospitalier de l’Universitaire Montréal, CHUM Hôtel Dieu, Département de Nutrition, Faculte du Medicine, QC, Canada – name: 8 Department of Medicine, McGill University, Montréal, QC, Canada – name: 19 Division of Senology, Department of Gynecology, Medical University of Vienna and Private Trust for Breast Health, Austria – name: 10 Department of Oncology, McGill University, Montréal, QC, Canada – name: 22 Mayo Clinic, Rochester, MN |
| Author_xml | – sequence: 1 givenname: Kelly A. surname: Metcalfe fullname: Metcalfe, Kelly A. – sequence: 2 givenname: Daphna surname: Birenbaum‐Carmeli fullname: Birenbaum‐Carmeli, Daphna – sequence: 3 givenname: Jan surname: Lubinski fullname: Lubinski, Jan – sequence: 4 givenname: Jacek surname: Gronwald fullname: Gronwald, Jacek – sequence: 5 givenname: Henry surname: Lynch fullname: Lynch, Henry – sequence: 6 givenname: Pal surname: Moller fullname: Moller, Pal – sequence: 7 givenname: Parviz surname: Ghadirian fullname: Ghadirian, Parviz – sequence: 8 givenname: William D. surname: Foulkes fullname: Foulkes, William D. – sequence: 9 givenname: Jan surname: Klijn fullname: Klijn, Jan – sequence: 10 givenname: Eitan surname: Friedman fullname: Friedman, Eitan – sequence: 11 givenname: Charmaine surname: Kim‐Sing fullname: Kim‐Sing, Charmaine – sequence: 12 givenname: Peter surname: Ainsworth fullname: Ainsworth, Peter – sequence: 13 givenname: Barry surname: Rosen fullname: Rosen, Barry – sequence: 14 givenname: Susan surname: Domchek fullname: Domchek, Susan – sequence: 15 givenname: Teresa surname: Wagner fullname: Wagner, Teresa – sequence: 16 givenname: Nadine surname: Tung fullname: Tung, Nadine – sequence: 17 givenname: Siranoush surname: Manoukian fullname: Manoukian, Siranoush – sequence: 18 givenname: Fergus surname: Couch fullname: Couch, Fergus – sequence: 19 givenname: Ping surname: Sun fullname: Sun, Ping – sequence: 20 givenname: Steven A. surname: Narod fullname: Narod, Steven A. email: steven.narod@wchospital.ca |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20145483$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18196574$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk9v1DAQxS1URLeFA18A5QJSD2n9N04uSGVVYFElJNSerYkzAZesE-xkq377ejfLChCIk581v3ke2--EHPneIyEvGT1nlPILd2fPuRCSPiELRiudU87UEVmkGs01E8UxOYnxjlLGFJXPyDErWVUoLRcEV37E4GF0vYcu20BwO505nwUYMWZ9m03DCN9xq4aAG_Sj26TdsOXiFnz3ZXnJMvDNTvFsPY2ziYUQHIb4nDxtoYv4Yr-ektv3VzfLj_n15w-r5eV1bpWkNBdWYyGhbnTJeWkpKwsBKEUtsdJ1Aa2SCoErgdjU2KqqLZuWc45N2VIlrTglb2ffYarX2Ng0aoDODMGtITyYHpz5veLdN_O13xheiULrMhm82RuE_seEcTRrFy12HXjsp2g0FbLkVP0XZJXiUukiga9-Hekwy88vSMDrPQDRQtcG8NbFA8cpk0qWInEXM2dDH2PA1lg3P3O6iesMo2YbBpPCYHZhSB1nf3QcDv8Lu3e_dx0-_Bs0q0_LueMRNB7EAA |
| CODEN | IJCNAW |
| CitedBy_id | crossref_primary_10_1245_s10434_012_2258_x crossref_primary_10_1093_annonc_mdy515 crossref_primary_10_1186_s12913_022_08372_w crossref_primary_10_3389_fonc_2016_00119 crossref_primary_10_1111_j_1399_0004_2012_01859_x crossref_primary_10_1177_2381468318821103 crossref_primary_10_1111_cge_12216 crossref_primary_10_1186_s13058_019_1132_1 crossref_primary_10_1002_ijc_32916 crossref_primary_10_1097_AOG_0b013e3182783c2f crossref_primary_10_1111_j_1399_0004_2009_01329_x crossref_primary_10_1007_s00198_020_05608_5 crossref_primary_10_1200_JCO_22_01609 crossref_primary_10_3389_fgene_2018_00624 crossref_primary_10_1016_j_ctrv_2017_09_005 crossref_primary_10_1097_AOG_0b013e318269b8b1 crossref_primary_10_1111_j_1399_0004_2008_01111_x crossref_primary_10_1007_s10689_013_9625_z crossref_primary_10_4061_2011_481563 crossref_primary_10_1097_CCO_0b013e3283139173 crossref_primary_10_1186_s12905_014_0150_5 crossref_primary_10_1002_cncr_30621 crossref_primary_10_1097_GCO_0b013e328332dca3 crossref_primary_10_1177_1609406917750973 crossref_primary_10_2217_thy_10_25 crossref_primary_10_1159_000343717 crossref_primary_10_1016_j_eujim_2016_04_001 crossref_primary_10_1007_s10689_009_9271_7 crossref_primary_10_1016_j_suc_2013_01_005 crossref_primary_10_1098_rsob_160230 crossref_primary_10_1038_s41416_019_0446_1 crossref_primary_10_1038_s41416_019_0484_8 crossref_primary_10_1080_07399332_2016_1267182 crossref_primary_10_1097_GCO_0b013e328335462f crossref_primary_10_1158_1055_9965_EPI_09_0171 crossref_primary_10_1007_s10549_018_5045_y crossref_primary_10_1158_1940_6207_CAPR_21_0141 crossref_primary_10_1001_jamaoncol_2018_0211 crossref_primary_10_1007_s10897_018_0254_4 crossref_primary_10_1177_0272989X14556130 crossref_primary_10_1186_1897_4287_12_9 crossref_primary_10_1007_s10549_009_0497_8 crossref_primary_10_1177_1049732314529666 crossref_primary_10_1007_s10549_010_1043_4 crossref_primary_10_1186_1897_4287_12_1 crossref_primary_10_1093_annonc_mdv590 crossref_primary_10_1159_000503370 crossref_primary_10_1097_IGC_0000000000000403 crossref_primary_10_5468_ogs_2015_58_4_284 crossref_primary_10_1002_14651858_CD002748_pub4 crossref_primary_10_1007_s10897_009_9245_9 crossref_primary_10_1111_ajco_13274 crossref_primary_10_1016_j_breast_2018_03_009 crossref_primary_10_1007_s10549_011_1423_4 crossref_primary_10_1097_GRF_0000000000000317 crossref_primary_10_1200_JCO_2008_17_4227 crossref_primary_10_1016_j_clbc_2016_06_016 crossref_primary_10_1016_j_currproblcancer_2016_09_007 crossref_primary_10_1245_s10434_013_3040_4 crossref_primary_10_3390_cancers16020248 crossref_primary_10_1111_j_1399_0004_2010_01444_x crossref_primary_10_3390_cancers14071786 crossref_primary_10_1038_nrclinonc_2012_102 crossref_primary_10_1200_JCO_2008_21_4684 crossref_primary_10_1007_s00268_010_0477_5 crossref_primary_10_1016_j_pec_2014_07_004 crossref_primary_10_1093_humrep_dex356 crossref_primary_10_1002_pon_5253 crossref_primary_10_1007_s12609_010_0026_0 crossref_primary_10_1016_j_ygyno_2018_10_014 crossref_primary_10_1200_JCO_2013_53_2820 crossref_primary_10_1016_j_amjsurg_2017_06_017 crossref_primary_10_1007_s10269_016_2595_7 crossref_primary_10_3346_jkms_2021_36_e241 crossref_primary_10_1002_cncr_26294 crossref_primary_10_5694_mja13_10848 crossref_primary_10_1007_s00432_015_2051_x crossref_primary_10_1097_SLA_0b013e318214b55a crossref_primary_10_1177_1049732314528756 crossref_primary_10_1158_1055_9965_EPI_09_0359 crossref_primary_10_1158_1055_9965_EPI_11_0991 crossref_primary_10_1186_s13058_019_1135_y crossref_primary_10_2217_WHE_14_82 crossref_primary_10_3390_cancers10110433 crossref_primary_10_1200_JCO_2009_26_3467 crossref_primary_10_1001_jamasurg_2019_5410 crossref_primary_10_1002_jgc4_1220 crossref_primary_10_2217_cpr_13_72 crossref_primary_10_1038_bjc_2014_109 crossref_primary_10_1007_s00129_014_3349_5 crossref_primary_10_1002_pon_3139 crossref_primary_10_1093_jnci_djt323 crossref_primary_10_1002_pon_2041 crossref_primary_10_1016_j_jacr_2017_03_016 crossref_primary_10_1007_s10549_013_2540_z crossref_primary_10_1097_AOG_0000000000003729 crossref_primary_10_1186_s12885_024_12003_4 crossref_primary_10_1016_j_maturitas_2011_08_001 crossref_primary_10_17816_onco39998 crossref_primary_10_1002_ajim_20962 crossref_primary_10_1111_j_1471_0528_2011_02920_x crossref_primary_10_1146_annurev_genom_083118_015253 crossref_primary_10_1097_PRS_0000000000003577 crossref_primary_10_1001_jamaoncol_2019_3323 crossref_primary_10_1007_s10549_010_1120_8 crossref_primary_10_1007_s10549_016_3685_3 crossref_primary_10_1089_gte_2008_0067 crossref_primary_10_1002_jso_24209 crossref_primary_10_1080_13697137_2018_1514006 crossref_primary_10_1097_NCC_0b013e3182642cb5 crossref_primary_10_1158_1055_9965_EPI_10_0082 crossref_primary_10_1158_1940_6207_CAPR_20_0411 crossref_primary_10_4000_sociologies_4508 crossref_primary_10_1007_s10552_014_0521_0 crossref_primary_10_1177_0003134820964208 crossref_primary_10_1016_j_clbc_2017_04_005 crossref_primary_10_1007_s10897_016_9973_6 crossref_primary_10_1038_s41416_018_0225_4 crossref_primary_10_1007_s10689_012_9588_5 crossref_primary_10_1007_s10689_012_9527_5 crossref_primary_10_1001_jamaoncol_2018_0644 crossref_primary_10_1177_107327481201900402 crossref_primary_10_1158_0008_5472_CAN_08_4005 crossref_primary_10_1007_s11864_016_0417_1 crossref_primary_10_1002_jgc4_1322 crossref_primary_10_1155_2011_374012 crossref_primary_10_1177_1457496913490460 crossref_primary_10_1038_ejhg_2015_268 crossref_primary_10_1002_humu_20972 crossref_primary_10_1016_j_bjps_2015_04_004 crossref_primary_10_1007_s10198_021_01396_9 crossref_primary_10_1188_11_ONF_572_581 crossref_primary_10_1007_s40615_024_02104_y crossref_primary_10_1200_OP_21_00322 crossref_primary_10_1111_j_1399_0004_2012_01855_x crossref_primary_10_1016_j_maturitas_2014_12_009 crossref_primary_10_1016_j_asjsur_2021_01_007 crossref_primary_10_1007_s00439_018_1944_6 crossref_primary_10_1684_bdc_2013_1708 crossref_primary_10_3390_cancers14071839 crossref_primary_10_1111_j_1399_0004_2010_01604_x crossref_primary_10_1200_JCO_2009_27_2294 crossref_primary_10_1007_s10549_014_3134_0 crossref_primary_10_1007_s10689_024_00412_0 crossref_primary_10_1111_cge_12298 crossref_primary_10_1111_tbj_13877 crossref_primary_10_1016_j_bpobgyn_2011_11_002 crossref_primary_10_1038_nrclinonc_2014_3 crossref_primary_10_1007_s10549_016_4029_z crossref_primary_10_1002_cam4_2836 crossref_primary_10_1002_ijc_28941 crossref_primary_10_1245_s10434_019_07982_9 crossref_primary_10_18370_2309_4117_2020_55_72_78 crossref_primary_10_2139_ssrn_3139779 crossref_primary_10_1007_s10689_017_0047_1 crossref_primary_10_1186_2041_1480_3_S2_S3 crossref_primary_10_1245_s10434_015_4896_2 crossref_primary_10_1002_cam4_70321 crossref_primary_10_1016_S1470_2045_10_70263_1 crossref_primary_10_1126_science_1251827 crossref_primary_10_1089_gtmb_2008_0067 crossref_primary_10_1158_1940_6207_CAPR_19_0506 crossref_primary_10_1016_j_ogc_2021_11_005 crossref_primary_10_1093_jnci_djn313 crossref_primary_10_2139_ssrn_2623263 crossref_primary_10_1016_j_critrevonc_2014_01_008 crossref_primary_10_1186_1472_6874_10_24 crossref_primary_10_1007_s10897_017_0148_x crossref_primary_10_1093_annonc_mdt327 crossref_primary_10_1200_JCO_2010_28_0719 crossref_primary_10_1007_s10549_018_4694_1 crossref_primary_10_1007_s10549_021_06410_5 crossref_primary_10_1038_bjc_2011_573 crossref_primary_10_1038_s41598_021_82654_x crossref_primary_10_1111_tbj_12521 crossref_primary_10_1136_ijgc_2021_002738 crossref_primary_10_1038_nrclinonc_2014_101 crossref_primary_10_1007_s10549_011_1941_0 crossref_primary_10_1007_s00129_017_4175_3 crossref_primary_10_1093_annonc_mdw043 crossref_primary_10_1001_jamanetworkopen_2019_8420 crossref_primary_10_1097_GME_0000000000000126 crossref_primary_10_1200_JCO_2011_38_6060 crossref_primary_10_1158_1055_9965_EPI_18_0584 crossref_primary_10_1186_s13058_023_01753_x crossref_primary_10_1200_EDBK_280625 crossref_primary_10_1080_07399332_2018_1424855 crossref_primary_10_3390_healthcare11162360 crossref_primary_10_1007_s11912_024_01560_3 crossref_primary_10_1200_JCO_2009_22_7991 crossref_primary_10_1016_j_ejso_2014_02_219 crossref_primary_10_2217_17455057_5_1_63 crossref_primary_10_1016_j_ogc_2013_05_009 crossref_primary_10_1001_jamaoncol_2019_6400 crossref_primary_10_1016_j_breast_2012_02_004 crossref_primary_10_1016_j_breast_2021_08_015 crossref_primary_10_1002_ajmg_a_33068 crossref_primary_10_1007_s10689_019_00142_8 crossref_primary_10_1200_JCO_2008_19_9067 crossref_primary_10_1016_j_ejso_2021_03_248 crossref_primary_10_1111_j_1399_0004_2008_00988_x crossref_primary_10_1007_s10897_016_9981_6 crossref_primary_10_1016_j_jogoh_2024_102760 crossref_primary_10_1016_j_ajog_2021_06_070 crossref_primary_10_1162_DRAM_a_00217 crossref_primary_10_1007_s12609_011_0049_1 crossref_primary_10_1016_j_ejca_2013_04_025 crossref_primary_10_1002_jgc4_1734 crossref_primary_10_3390_genes16010082 crossref_primary_10_1136_bmjopen_2018_025317 crossref_primary_10_1002_cncr_28879 crossref_primary_10_1002_cncr_33668 crossref_primary_10_1200_JCO_2012_47_8313 crossref_primary_10_1245_s10434_015_4537_9 crossref_primary_10_1016_j_jval_2019_03_008 crossref_primary_10_3390_cancers10120524 crossref_primary_10_1080_13557858_2018_1562053 crossref_primary_10_2217_bmt_14_47 crossref_primary_10_1148_radiol_2017161218 crossref_primary_10_1097_GCO_0000000000000140 crossref_primary_10_1093_annonc_mdq663 crossref_primary_10_1016_j_mayocp_2019_02_017 crossref_primary_10_1093_annonc_mdq665 crossref_primary_10_1002_mgg3_1867 crossref_primary_10_1007_s12687_016_0266_4 crossref_primary_10_3390_curroncol31010023 crossref_primary_10_1111_cge_12149 crossref_primary_10_1002_mgg3_2031 crossref_primary_10_1007_s10689_011_9484_4 crossref_primary_10_1007_s10549_017_4332_3 crossref_primary_10_1016_j_jmig_2017_10_025 crossref_primary_10_1016_j_clbc_2024_09_018 crossref_primary_10_1111_j_1468_0009_2009_00563_x crossref_primary_10_1080_0284186X_2018_1481291 crossref_primary_10_1016_j_ygyno_2011_04_004 crossref_primary_10_1158_1078_0432_CCR_09_2953 crossref_primary_10_1111_cge_12233 crossref_primary_10_1016_j_erap_2021_100714 crossref_primary_10_1200_JCO_2011_40_1562 crossref_primary_10_2217_WHE_12_41 crossref_primary_10_1038_nrclinonc_2010_166 crossref_primary_10_3390_cancers15041090 crossref_primary_10_1007_s40258_020_00599_0 crossref_primary_10_1002_pon_5166 crossref_primary_10_1245_s10434_017_5976_2 crossref_primary_10_1016_j_breast_2011_04_005 crossref_primary_10_1371_journal_pone_0218188 crossref_primary_10_1007_s10689_010_9333_x crossref_primary_10_1200_JCO_2013_52_8331 crossref_primary_10_1016_j_ajog_2010_05_038 crossref_primary_10_1017_S0029665112002741 crossref_primary_10_3390_genes12071100 crossref_primary_10_1016_j_ajog_2013_01_026 crossref_primary_10_1007_s10549_020_05949_z crossref_primary_10_1136_ijgc_2023_004801 crossref_primary_10_1016_j_soc_2015_06_011 crossref_primary_10_1016_j_soc_2008_08_008 crossref_primary_10_1016_j_ygyno_2016_07_104 crossref_primary_10_1111_j_1471_0528_2011_03257_x |
| Cites_doi | 10.1056/NEJMoa031759 10.1093/jnci/94.20.1564 10.1086/375033 10.1002/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V 10.1002/ajmg.a.10102 10.1016/S0140-6736(05)66481-1 10.1200/JCO.2003.01.088 10.1054/bjoc.1999.1086 10.3322/canjclin.57.2.75 10.1200/JCO.2004.00.7138 10.1016/S0140-6736(00)03258-X 10.1200/JCO.2004.04.033 10.1038/sj.ejhg.5200418 10.2105/AJPH.85.6.801 10.1001/jama.292.11.1317 10.1016/S0140-6736(00)02347-3 10.1056/NEJM199901143400201 10.1200/JCO.2003.02.107 10.1056/NEJM200107193450301 10.1093/jnci/90.18.1371 10.1002/(SICI)1097-0142(19970601)79:11<2219::AID-CNCR21>3.0.CO;2-Y 10.1001/jama.296.2.185 10.1002/pon.726 10.1023/A:1015269620265 10.1093/jnci/93.21.1633 10.1006/pmed.2000.0684 10.1111/j.1399-0004.2006.00665.x 10.1086/301749 10.1007/s10689-005-4215-3 10.1136/jmg.37.11.866 |
| ContentType | Journal Article |
| Copyright | Copyright © 2008 Wiley‐Liss, Inc. 2008 INIST-CNRS (c) 2008 Wiley-Liss, Inc. |
| Copyright_xml | – notice: Copyright © 2008 Wiley‐Liss, Inc. – notice: 2008 INIST-CNRS – notice: (c) 2008 Wiley-Liss, Inc. |
| CorporateAuthor | and the Hereditary Breast Cancer Clinical Study Group Hereditary Breast Cancer Clinical Study Group |
| CorporateAuthor_xml | – name: and the Hereditary Breast Cancer Clinical Study Group – name: Hereditary Breast Cancer Clinical Study Group |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO 7U1 8FD C1K FR3 H94 P64 RC3 7X8 5PM |
| DOI | 10.1002/ijc.23340 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Risk Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Risk Abstracts Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Risk Abstracts MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0215 |
| EndPage | 2022 |
| ExternalDocumentID | PMC2936778 18196574 20145483 10_1002_ijc_23340 IJC23340 |
| Genre | article Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | Canada Europe |
| GeographicLocations_xml | – name: Canada – name: Europe |
| GrantInformation_xml | – fundername: New Investigator Award from the Canadian Institutes of Health Research – fundername: NCI NIH HHS grantid: P50 CA116201 |
| GroupedDBID | --- -~X .3N .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EX3 F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WOW WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZZTAW ~IA ~WT .GJ 3O- 8WZ A6W AANHP AAYXX ABEFU ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEYWJ AGHNM AGQPQ AGYGG AHEFC AI. ASPBG AVWKF AZFZN BDRZF CITATION EMOBN FEDTE GLUZI HF~ HVGLF M6P PALCI SAMSI VH1 Y6R ZGI ZXP AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7TO 7U1 8FD C1K FR3 H94 P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c5400-3c7e64abd78228c01863ae43b4e97b6af545ea253eedbef59f8df222ed8f054c3 |
| IEDL.DBID | DR2 |
| ISSN | 0020-7136 1097-0215 |
| IngestDate | Thu Aug 21 13:55:11 EDT 2025 Fri Jul 11 04:55:22 EDT 2025 Fri Jul 11 04:35:31 EDT 2025 Fri May 30 11:01:09 EDT 2025 Mon Jul 21 09:11:53 EDT 2025 Thu Apr 24 23:10:12 EDT 2025 Tue Jul 01 02:27:17 EDT 2025 Wed Jan 22 16:21:58 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Human ovarian cancer Ovary cancer Breast cancer Malignant tumor BRCA1 BRCA2 Female genital diseases Prevention Mammary gland diseases Ovarian diseases Cancerology BRCA2 gene Genetics Mutation Carrier BRCA1 gene Public health Cancer Tumor suppressor gene |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 (c) 2008 Wiley-Liss, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5400-3c7e64abd78228c01863ae43b4e97b6af545ea253eedbef59f8df222ed8f054c3 |
| Notes | Fax: +416‐351‐3766 Other Members of the Hereditary Breast Cancer Clinical Study Group are as follows: M. Daly, Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA, USA; H.M. Saal, Hereditary Cancer Program, Division of Human Genetics, Children's Hospital Medical Center, Cincinnati, OH, USA; K. Sweet, Clinical Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus OH, USA; Dominique Lyonnet, Department of Oncology Genetics, Institut Curie, Paris, France; A. Eisen, Cancer Risk Assessment Clinic, Juravinksi Cancer Centre (Hamilton Regional Cancer Centre), Hamilton, ON, Canada; G. Rennert, National Cancer Control Center, Carmel Medical Center, Haifa, Israel; J. McLennan, University of San Francisco, California, USA; R. Gershoni‐Baruch, Institute of Genetics, Rambam Medical Center, Haifa, Israel; J. Garber, Dana Farber Cancer Center; S. Cummings, Center for Clinical Cancer Genetics, University of Chicago, Chicago, IL, USA; J. Weitzel, Department of Cancer Genetics, City of Hope National Medical Center, Duarte, California, USA; B. Karlan and R.N. Kurz, Gynecology Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA; W. McKinnon and M. Wood, University of Vermont; D. Gilchrist, University of Alberta; A. Chudley, University of Manitoba, Winnipeg, Manitoba; M. Osborne, Strang Cancer Prevention Centre, New York, NY, USA; David Fishman, New York University School of Medicine, New York, NY; W.S. Meschino, North York General, North York, ON, Canada; ; E. Lemire, Division of Medical Genetics, Royal University Hospital and the University of Saskatchewan, Saskatoon, Canada; C. Maugard, University of Montreal, Quebec, Canada; G. Mills, MD Anderson Cancer Center, Houston, TX; S. Merajver, University of Michigan Comprehensive Cancer Center; D. Rayson, Queen Elizabeth Health Sciences Centre, Halifax, Nova Scotia, Canada; J.M. Collee, Department of Clinical Genetics, Erasmus MC, Rotterdam. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.23340 |
| PMID | 18196574 |
| PQID | 19524576 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2936778 proquest_miscellaneous_70348205 proquest_miscellaneous_19524576 pubmed_primary_18196574 pascalfrancis_primary_20145483 crossref_citationtrail_10_1002_ijc_23340 crossref_primary_10_1002_ijc_23340 wiley_primary_10_1002_ijc_23340_IJC23340 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 1 May 2008 |
| PublicationDateYYYYMMDD | 2008-05-01 |
| PublicationDate_xml | – month: 05 year: 2008 text: 1 May 2008 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
| PublicationTitle | International journal of cancer |
| PublicationTitleAlternate | Int J Cancer |
| PublicationYear | 2008 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
| References | 2006; 70 2004; 22 2001; 92 2001; 93 2000; 355 2000; 356 2002; 94 2002; 73 2000; 8 1999; 340 2006; 296 1998; 62 2003; 72 2007; 57 2005; 23 2001; 345 1995; 85 2004; 351 2003; 118A 2000; 37 2005; 365 1997; 79 2004; 292 2000; 31 2004; 13 2005; 4 1998; 90 2000; 82 2007; 1 2003; 21 e_1_2_6_31_2 e_1_2_6_30_2 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_32_2 e_1_2_6_16_2 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_20_2 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 Metcalfe K (e_1_2_6_27_2) 2007; 1 e_1_2_6_24_2 Wagner TM (e_1_2_6_15_2) 2000; 82 e_1_2_6_23_2 e_1_2_6_2_2 e_1_2_6_22_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_26_2 e_1_2_6_25_2 |
| References_xml | – volume: 351 start-page: 427 year: 2004 end-page: 37 article-title: Efficacy of MRI and mammography for breast‐cancer screening in women with a familial or genetic predisposition publication-title: N Engl J Med – volume: 23 start-page: 7491 year: 2005 end-page: 6 article-title: Breast cancer risk following bilateral oophorectomy in and mutation carriers: an international case‐control study publication-title: J Clin Oncol – volume: 73 start-page: 97 year: 2002 end-page: 112 article-title: One year follow‐up of women opting for presymptomatic testing for and : emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery) publication-title: Breast Cancer Res Treat – volume: 340 start-page: 77 year: 1999 end-page: 85 article-title: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer publication-title: N Engl J Med – volume: 37 start-page: 866 year: 2000 end-page: 74 article-title: An evaluation of needs of female and carriers undergoing genetic counselling publication-title: J Med Genet – volume: 90 start-page: 1371 year: 1998 end-page: 88 article-title: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‐1 study publication-title: J Natl Cancer Inst – volume: 118A start-page: 201 year: 2003 end-page: 9 article-title: Genetic testing for a mutation: prophylactic surgery and screening behavior in women 2 years post testing publication-title: Am J Med Genet – volume: 4 start-page: 97 year: 2005 end-page: 103 article-title: The use of preventive measures among healthy women who carry a or mutation publication-title: Fam Cancer – volume: 92 start-page: 959 year: 2001 end-page: 68 article-title: Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women publication-title: Cancer – volume: 70 start-page: 198 year: 2006 end-page: 206 article-title: Risk‐reducing surgery, screening and chemoprevention practices of and mutation carriers: a prospective cohort study publication-title: Clin Genet – volume: 365 start-page: 1769 year: 2005 end-page: 78 article-title: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) publication-title: Lancet – volume: 93 start-page: 1633 year: 2001 end-page: 7 article-title: Efficacy of bilateral prophylactic mastectomy in and gene mutation carriers publication-title: J Natl Cancer Inst – volume: 1 start-page: E92 year: 2007 end-page: E98 article-title: Variation in rates of uptake of preventive options in and mutation carriers across Canada publication-title: Open Med – volume: 292 start-page: 1317 year: 2004 end-page: 25 article-title: Surveillance of and mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination publication-title: JAMA – volume: 57 start-page: 75 year: 2007 end-page: 89 article-title: American cancer society guidelines for breast screening with MRI as an adjunct to mammography publication-title: CA Cancer J Clin – volume: 345 start-page: 158 year: 2001 end-page: 64 article-title: Breast cancer after prophylactic bilateral mastectomy in women with a or mutation publication-title: N Engl J Med – volume: 79 start-page: 2219 year: 1997 end-page: 28 article-title: A descriptive study of testing and reactions to desclosure of test results publication-title: Cancer – volume: 296 start-page: 185 year: 2006 end-page: 92 article-title: Salpingo‐oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a or Mutation publication-title: JAMA – volume: 22 start-page: 2328 year: 2004 end-page: 35 article-title: Contralateral breast cancer in and mutation carriers publication-title: J Clin Oncol – volume: 21 start-page: 4034 year: 2003 end-page: 41 article-title: Bilateral prophylactic oophorectomy and ovarian cancer screening following / mutation testing publication-title: J Clin Oncol – volume: 31 start-page: 75 year: 2000 end-page: 80 article-title: Prophylactic surgery decisions and surveillance practices one year following /2 testing publication-title: Prev Med – volume: 356 start-page: 1876 year: 2000 end-page: 81 article-title: Tamoxifen and risk of contralateral breast cancer in and mutation carriers: a case‐control study. Hereditary Breast Cancer Clinical Study Group publication-title: Lancet – volume: 8 start-page: 204 year: 2000 end-page: 8 article-title: Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines publication-title: Eur J Hum Genet – volume: 13 start-page: 14 year: 2004 end-page: 25 article-title: Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy publication-title: Psychooncology – volume: 82 start-page: 1249 year: 2000 end-page: 53 article-title: Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group publication-title: Br J Cancer – volume: 85 start-page: 801 year: 1995 end-page: 5 article-title: The practice of prophylactic mastectomy: a survey of Maryland surgeons publication-title: Am J Public Health – volume: 62 start-page: 676 year: 1998 end-page: 89 article-title: Genetic heterogeneity and penetrance analysis of the and genes in breast cancer families. The Breast Cancer Linkage Consortium publication-title: Am J Hum Genet – volume: 72 start-page: 1117 year: 2003 end-page: 30 article-title: Average risks of breast and ovarian cancer associated with or mutations detected in case series unselected for family history: a combined analysis of 22 studies publication-title: Am J Hum Genet – volume: 94 start-page: 1564 year: 2002 end-page: 9 article-title: Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy publication-title: J Natl Cancer Inst – volume: 355 start-page: 2015 year: 2000 end-page: 20 article-title: Presymptomatic DNA testing and prophylactic surgery in families with a or mutation publication-title: Lancet – volume: 21 start-page: 4322 year: 2003 end-page: 28 article-title: Tamoxifen as chemoprevention in /2 carriers with breast cancer: a pilot survey of physicians publication-title: J Clin Oncol – ident: e_1_2_6_10_2 doi: 10.1056/NEJMoa031759 – ident: e_1_2_6_32_2 doi: 10.1093/jnci/94.20.1564 – ident: e_1_2_6_3_2 doi: 10.1086/375033 – ident: e_1_2_6_26_2 doi: 10.1002/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V – ident: e_1_2_6_24_2 doi: 10.1002/ajmg.a.10102 – ident: e_1_2_6_11_2 doi: 10.1016/S0140-6736(05)66481-1 – ident: e_1_2_6_23_2 doi: 10.1200/JCO.2003.01.088 – volume: 82 start-page: 1249 year: 2000 ident: e_1_2_6_15_2 article-title: Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group publication-title: Br J Cancer doi: 10.1054/bjoc.1999.1086 – ident: e_1_2_6_31_2 doi: 10.3322/canjclin.57.2.75 – ident: e_1_2_6_5_2 doi: 10.1200/JCO.2004.00.7138 – ident: e_1_2_6_20_2 doi: 10.1016/S0140-6736(00)03258-X – ident: e_1_2_6_8_2 doi: 10.1200/JCO.2004.04.033 – ident: e_1_2_6_29_2 doi: 10.1038/sj.ejhg.5200418 – ident: e_1_2_6_28_2 doi: 10.2105/AJPH.85.6.801 – ident: e_1_2_6_9_2 doi: 10.1001/jama.292.11.1317 – ident: e_1_2_6_25_2 doi: 10.1016/S0140-6736(00)02347-3 – ident: e_1_2_6_18_2 doi: 10.1056/NEJM199901143400201 – ident: e_1_2_6_30_2 doi: 10.1200/JCO.2003.02.107 – ident: e_1_2_6_19_2 doi: 10.1056/NEJM200107193450301 – ident: e_1_2_6_7_2 doi: 10.1093/jnci/90.18.1371 – ident: e_1_2_6_12_2 doi: 10.1002/(SICI)1097-0142(19970601)79:11<2219::AID-CNCR21>3.0.CO;2-Y – ident: e_1_2_6_6_2 doi: 10.1001/jama.296.2.185 – ident: e_1_2_6_21_2 doi: 10.1002/pon.726 – ident: e_1_2_6_14_2 doi: 10.1023/A:1015269620265 – volume: 1 start-page: E92 year: 2007 ident: e_1_2_6_27_2 article-title: Variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers across Canada publication-title: Open Med – ident: e_1_2_6_4_2 doi: 10.1093/jnci/93.21.1633 – ident: e_1_2_6_16_2 doi: 10.1006/pmed.2000.0684 – ident: e_1_2_6_17_2 doi: 10.1111/j.1399-0004.2006.00665.x – ident: e_1_2_6_2_2 doi: 10.1086/301749 – ident: e_1_2_6_22_2 doi: 10.1007/s10689-005-4215-3 – ident: e_1_2_6_13_2 doi: 10.1136/jmg.37.11.866 |
| SSID | ssj0011504 |
| Score | 2.4310572 |
| Snippet | Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening.... Several options for cancer prevention are available for women with a BRCA1 or BRCA2 mutation, including prophylactic surgery, chemoprevention and screening.... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2017 |
| SubjectTerms | Adult Aged Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences BRCA1 BRCA2 breast cancer Breast Neoplasms - genetics Breast Neoplasms - prevention & control Canada - epidemiology Chi-Square Distribution Estrogen Receptor Modulators - therapeutic use Europe - epidemiology Female Genes, BRCA1 Genes, BRCA2 Genetic Variation Gynecology. Andrology. Obstetrics Heterozygote Humans Mammary gland diseases Mass Screening Mastectomy - statistics & numerical data Medical sciences Middle Aged Mutation ovarian cancer Ovariectomy - statistics & numerical data Population Surveillance prevention Primary Prevention - methods Raloxifene Hydrochloride - therapeutic use Research Design Surveys and Questionnaires Tamoxifen - therapeutic use Tumors |
| Title | International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.23340 https://www.ncbi.nlm.nih.gov/pubmed/18196574 https://www.proquest.com/docview/19524576 https://www.proquest.com/docview/70348205 https://pubmed.ncbi.nlm.nih.gov/PMC2936778 |
| Volume | 122 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0020-7136 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1097-0215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011504 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPSAkxPuxPIqFOHDJNontPMSprKhKpXKoqNQDUmQ7troUsqtm0wO_nhk7SQm0EuLmJBMlnszY39iTbwDeFsrgLKnjSHLJI6FLg-OgEZFQiY1rYYwT9KPw0efs4EQcnsrTLXg__AsT-CHGBTfyDD9ek4Mr3e5ekYYuv5l5yrmgeD3h0m_RHo_UUQR0egbmOMJALBtYheJ0d7xzMhfdWasW1eJCPYvrAOffeZO_41k_Ie3fg69DV0Ieyvm82-i5-fkHy-N_9vU-3O2BKtsLlvUAtmzzEG4d9Vvxj8BO1hLZJcbcvs2WDSP6iZatHOvWG3VuqbXuqaIu8Sjk0ZDgh-PFXsJUU_tWyn50ITOAGXVBpfTax3Cy__HL4iDqazZEBrEfDukmt5lQuibkUZg4KTKurOBa2DLXmXKI2KxKJce5WVsnS1fUDjGKrQuH6NHwJ7DdrBr7DFicm1IJqzUvnMil0XFpOZ5AQJXpLOYzeDd8vcr0hOZUV-N7FaiY0wrVVnm1zeDNKLoOLB7XCe1MTGCUTGnrVRT4wNeDTVTohLSzohq76toqKWUqMHK7WQIHVoFgS87gabChq_coiNQxFzPIJ9Y1ChAB-PRKszzzROAI1Yj_DxXhjefmrlWfDhe-8fzfRV_A7ZAbQ8mdL2F7c9HZVwjANnrHe9ovnrot3w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRQKkinfL8mgtxIFLttnYeUlcykK1Ld0eqlbqBUW2Y4ulkF11Nz3w65mxk5RAKyFuTjJRYmdm_I09-QbgbSY1zpIqDGIe80CoXKMf1CIQcmTCUmhtBf0oPD1OJmfi8Dw-X4P37b8wnh-iW3Ajy3D-mgycFqR3r1lDZ9_0MOJcYMB-h_bnyCw_nnTkUQR1Gg7mMMBQLGl5hcJot7u1NxttLOQSB8b6ihY3Qc6_Myd_R7RuStp_CF_azvhMlIthvVJD_fMPnsf_7e0jeNBgVbbnlesxrJnqCdydNrvxT8H0lhPZFYbdrs1mFSMGiiWbW1YvVvLCUGvRsEVd4ZFPpSHBDyfjvRGTVelaEftR--QApuUlVdNbPoOz_U-n40nQlG0INMI_9Oo6NYmQqiTwkelwlCVcGsGVMHmqEmkRtBkZxRynZ2VsnNustAhTTJlZBJCab8J6Na_Mc2BhqnMpjFI8syKNtQpzw_EEYqpEJSEfwLv28xW64TSn0hrfC8_GHBU4bIUbtgG86UQXnsjjJqHtng50khHtvooMH7jTKkWBdkibK7Iy83pZjPI4Ehi83S6BvlUg3ooHsOWV6Po9MuJ1TMUA0p56dQLEAd6_Us2-Oi5wRGtEAYgD4bTn9q4VB4dj13jx76I7cG9yOj0qjg6OP7-E-z5VhnI9X8H66rI2rxGPrdS2M7tfVWsx-w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRaqQUHnD8mgtxIFLttl48hKnsrBqC61QRaUekCLbscXSko26mx749YztJCXQSoibk0yUeDKe-caefAZ4nQlFUVKGQcxjHqDMFflBhQGKiQ5LVMqg_VH48CjZO8GD0_h0Dd52_8J4foh-ws2ODOev7QCvS7NzRRo6_67GEedI-fotTCi7sojouOeOskinpWAOA8rEko5WKIx2-lsHwehOLZakF-M3tLgOcf5dOPk7oHURaXYXvnZ98YUoZ-NmJcfq5x80j__Z2Xuw2SJVtutN6z6s6eoBbBy2a_EPQQ8mE9klJd2uzeYVs_wTS7YwrKlX4kzbVt1yRV3SkS-ksYLvjqe7Eyaq0rUi9qPxpQFMiQu7l97yEZzMPnyZ7gXtpg2BIvBHPl2lOkEhSws9MhVOsoQLjVyizlOZCEOQTYso5hScpTZxbrLSEEjRZWYIPir-GNarRaWfAgtTlQvUUvLMYBorGeaa0wlCVIlMQj6CN93XK1TLaG431jgvPBdzVJDaCqe2EbzqRWtP43Gd0NbABHrJyK69YkYP3O5soqBRaJdWRKUXzbKY5HGElLrdLEGeFQltxSN44m3o6j0yy-qY4gjSgXX1ApYBfHilmn9zTOCE1SwBICnCGc_NXSv2D6au8ezfRbdh4_P7WfFp_-jjc7jt62RsoecLWF9dNPolgbGV3HKD7hejyzCq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+variation+in+rates+of+uptake+of+preventive+options+in+BRCA1+and+BRCA2+mutation+carriers&rft.jtitle=International+journal+of+cancer&rft.au=Metcalfe%2C+Kelly+A.&rft.au=Birenbaum-Carmeli%2C+Daphna&rft.au=Lubinski%2C+Jan&rft.au=Gronwald%2C+Jacek&rft.date=2008-05-01&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=122&rft.issue=9&rft.spage=2017&rft.epage=2022&rft_id=info:doi/10.1002%2Fijc.23340&rft_id=info%3Apmid%2F18196574&rft.externalDocID=PMC2936778 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |